Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6666440 | 0.80 | MAPT (0.37) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| SCHEMBL13158755 | 0.77 | MAPT (0.39) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| SCHEMBL9237452 | 0.73 | — | — | |
| SCHEMBL3686616 | 0.72 | MAPT (0.36) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| SCHEMBL1149412 | 0.72 | MAPT (0.36) | MAPTSLC22A16TSHRCHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL8056355 | 0.71 | — | — | |
| SCHEMBL193840 | 0.69 | — | — | |
| SCHEMBL9748138 | 0.69 | — | — | |
| SCHEMBL9748670 | 0.69 | — | — | |
| SCHEMBL9393610 | 0.69 | MAPT (0.42) | MAPTSLC22A16TSHRCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551445-B2 | Preparation and use of alkylating agents | THE QUEEN'S MEDICAL CENTER (US) | 2013-10-08 | — | — | US | disclosed |
| US-8554373-B2 | Preparation and use of alkylating agents | THE QUEEN'S MEDICAL CENTER (US) | 2013-10-08 | — | — | US | disclosed |
| US-7776309-B2 | Preparation and use of alkylating agents | THE QUEEN'S MEDICAL CENTER (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080294289-A1 | Preparation and Use of Alkylating Agents | THE QUEEN'S MEDICAL CENTER (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1660433-A2 | PREPARATION AND USE OF ALKYLATING AGENTS | The Queen's Medical Center (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050123475-A1 | Preparation and use of alkylating agents | THE QUEEN'S MEDICAL CENTER | 2005-06-09 | — | — | US | disclosed |
| WO-2005009928-A2 | PREPARATION AND USE OF ALKYLATING AGENTS | THE QUEEN'S MEDICAL CENTER (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050123475-A1 | Preparation and use of alkylating agents | MGMT, MCL1, TOP2A | MAPT 4689/4885SLC22A16 3432/4885TSHR 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.